期刊
THERAPEUTIC ADVANCES IN PSYCHOPHARMACOLOGY
卷 5, 期 1, 页码 43-58出版社
SAGE PUBLICATIONS LTD
DOI: 10.1177/2045125314557797
关键词
amphetamine; cannabis; drug models; kappa opioid; ketamine; LSD; models; PCP; psilocybin; psychosis; salvia divinorum; schizophrenia; THC
资金
- NIHR Biomedical Research Centre for Mental Health at the South London
- Maudsley NHS Foundation Trust
- Institute of Psychiatry, King's College London
Schizophrenia is a complex mental health disorder with positive, negative and cognitive symptom domains. Approximately one third of patients are resistant to currently available medication. New therapeutic targets and a better understanding of the basic biological processes that drive pathogenesis are needed in order to develop therapies that will improve quality of life for these patients. Several drugs that act on neurotransmitter systems in the brain have been suggested to model aspects of schizophrenia in animals and in man. In this paper, we selectively review findings from dopaminergic, glutamatergic, serotonergic, cannabinoid, GABA, cholinergic and kappa opioid pharmacological drug models to evaluate their similarity to schizophrenia. Understanding the interactions between these different neurotransmitter systems and their relationship with symptoms will be an important step towards building a coherent hypothesis for the pathogenesis of schizophrenia.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据